Hyperimmune immunoglobulin for people with COVID-19
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID‐19; and to maintain the currency of the evidence.
Main Authors: | Kimber, C, Valk, SJ, Chai, KL, Piechotta, V, Iannizzi, C, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cochrane Collaboration
2021
|
Similar Items
-
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
by: Piechotta, V, et al.
Published: (2021) -
Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
by: Valk, SJ, et al.
Published: (2021) -
Immunoglobulin replacement to prevent infections in people with haematological malignancies and haematopoietic stem cell transplantation
by: Chai, KL, et al.
Published: (2024) -
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
by: Hirsch, C, et al.
Published: (2021) -
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
by: Kreuzberger, N, et al.
Published: (2021)